Prosecution Insights
Last updated: November 11, 2026
Application No. 16/991,925

LABYRINTHULOMYCETE STRAINS FOR PRODUCING DOCOSAHEXAENOIC ACID

Final Rejection §102§103
Filed
Aug 12, 2020
Priority
May 22, 2014 — provisional 62/002,107 +1 more
Examiner
TICHY, JENNIFER M.H.
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Synthetic Genomics Inc.
OA Round
6 (Final)
64%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
400 granted / 620 resolved
+4.5% vs TC avg
Strong +34% interview lift
Without
With
+34.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
61 currently pending
Career history
709
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
39.4%
-0.6% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
30.6%
-9.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 620 resolved cases

Office Action

§102 §103
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This Office Action is in response to the paper filed 29 January 2026 and the Petition decision of 27 February 2026. Claims 1 and 14 have been amended. Claims 15 and 16 are newly added, however claim 15 is withdrawn as being drawn to non-elected species NRRL number 50836. It is noted that claims 6 and 7 are identified as “previously presented,” however, these claims were withdrawn in the last Office Action, as Applicant removed the elected species. Therefore, claims 6, 7, 10, 11, 15, and the species NRRL number 50836 in claim 1, are withdrawn. Claims 1, 5, 14, and 16 are currently pending and under examination. This application is a Continuation Application of U.S. Patent Application No. 14/720679, filed May 22, 2015, which claims benefit of priority to U.S. Provisional Patent Application No. 62/002107, filed May 22, 2014. New/Modified Objections/Rejections Necessitated by Amendment: Claim Objections Claim 16 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 5, and 14 are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Pora et al. (IDS; WO 2012/175027, Published 2012). With regard to claims 1, 5, and 14, Pora et al. teach a mutant Schizochytrium sp. strain identified as 2010-0321, wherein this strain comprises an 18S rDNA sequence having 98% identity to SEQ ID NO: 10 (Abs.; claim 1, 2, 4, 16; see also Sequence Comparison of current SEQ ID NO: 10 to Pora et al. SEQ ID NO: 2- Previously Presented). As currently written, Applicant claims either the mutant Labyrinthulomycete microorganism deposited under NRRL number 50837, or a descendent strain thereof that comprises an 18S rDNA sequence having at least 90% identity, or at least 98% identity, to SEQ ID NO: 10. As Schizochytrium sp. strain 2010-0321 of Pora et al. comprises an 18S rDNA sequence having 98% identity to SEQ ID NO: 10, Schizochytrium sp. strain 2010-0321 is structurally identical to, and therefore is, a descendant of the mutant Labyrinthulomycete microorganism deposited under NRRL number 50837 as claimed. Alternatively, it would have been obvious to one of ordinary skill in the art to utilize an alternative strain having a 18S rDNA sequence nearly identical to Schizochytrium sp. strain 2010-0321 to provide a strain for producing lipids as desired by Pora et al. As the mutant Schizochytrium sp. strain identified as 2010-0321 comprising an 18S rDNA sequence having 98% identity to SEQ ID NO: 10 of Pora et al. cannot be separated from its properties, the mutant Schizochytrium sp. strain identified as 2010-0321 would necessarily produce a microbial oil comprising at least 35% of total fatty acids as DHA and at least 25% of total fatty acids as myristic acid, as well as produce DHA at a rate of at least 100 mg/L/h, and produce at least 20% more DHA and at least 100% more myristic acid as a percent of total fatty acids than the wild type strain from which it is derived. Response to Arguments Applicant urges that Pora et al. do not teach the claims as amended. Applicant’s arguments have been fully considered, but have not been found persuasive for the reasons set forth in the new/modified rejection above. Conclusion No claims are allowable; however, claim 16 appears to be free of the art. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER M.H. TICHY whose telephone number is (571)272-3274. The examiner can normally be reached Monday-Thursday, 9:00am-7:00pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sharmila G. Landau can be reached on (571)272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JENNIFER M.H. TICHY/Primary Examiner, Art Unit 1653
Read full office action

Prosecution Timeline

Show 11 earlier events
Jun 18, 2024
Request for Continued Examination
Aug 22, 2024
Examiner Interview Summary
Aug 22, 2024
Applicant Interview (Telephonic)
Aug 28, 2024
Response after Non-Final Action
Jan 03, 2025
Non-Final Rejection mailed — §102, §103
Jul 12, 2025
Response after Non-Final Action
Jan 21, 2026
Response Filed
Sep 30, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773430
ANTI-BIOFILM AGENTS AND USES THEREOF
5y 6m to grant Granted Oct 27, 2026
Patent 12714729
Method of preparing a faecal microbiota sample
5y 6m to grant Granted Aug 25, 2026
Patent 12702979
Isolation of Different Extracellular Vesicle (EV) Subpopulations
4y 9m to grant Granted Aug 11, 2026
Patent 12697414
ADIPOSE COMPOSITIONS AND METHODS OF USE THEREOF
2y 4m to grant Granted Aug 04, 2026
Patent 12690582
VIABLE CELL COMPOSITIONS, AND METHODS RELATED TO SAME
6y 6m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+34.1%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 620 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month